Media: Richter's new uterine fibroid drug could sell EUR 80 mln/yr - MTI cites Vilaggazdasag

Richter Gedeon Vegyeszeti Gyar Nyrt

20/05/2020 09:57

May 20 (Reuters) - A Richter Gedeon Vegyeszeti Gyar Nyrt.
 GDRB.BU  statement for the daily Vilaggazdasag was quoted by
national news agency MTI as follows:
    * New uterine fibroid drug Relugolix sales could reach EUR
80m a
year if the drug is cleared to treat both uterine fibroids and
endometriosis;
    * Richter expects Relugolix to be available in the European
Union
from H2 2021, after approval by the European Medicines Agency,
in the CIS in 2022, in Latin America in 2023-24, and in
Australia and New Zealand in 2023;
    * Relugolix is expected to be available for the treatment of
endometriosis in Europe from the end of 2022 or early in 223,
and in the CIS, Latin America, Australia and New Zealand in
2024;
    * Phase III clinical trials of Relugolix for the treatment
of
endometriosis are under way.
    * Richter in exclusive agreement with Myovant Sciences to
sell
Relugolix  urn:newsml:reuters.com:*:nS8N2B206V

Further company coverage:  GDRB.BU 

 (Reporting by Marton Dunai)
 ((marton.dunai@thomsonreuters.com;))